Open Access Full Text Article

Dovepress

Prognostic factors for cesarean section outcome of pregnant women with gestational diabetes mellitus: a systematic review and meta-analysis

This article was published in the following Dove Press journal: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Jinjing Wang^{1,2,*} Kang Chen^{1,*} Xinye Jin¹ Xueqiong Li³ Ping An¹ Nan Yang⁴ Yaolong Chen⁴ Yi Fang² Yiming Mu¹

¹Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, People's Republic of China; ²Department of Endocrinology, Fifth Medical Center of PLA General Hospital, Beijing 100071, People's Republic of China; ³Department of Gerontology, First Affiliated Hospital of Kunming Medical University, Kunming 650031, People's Republic of China; ⁴Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, People's Republic of China

*These authors contributed equally to this work

Correspondence: Yiming Mu Department of Endocrinology, Chinese PLA General Hospital, No. 28, Fuxing Road, Haidian District, Beijing 100853, People's Republic of China Tel +86 189 1096 8729 Email muyiming@301hospital.com.cn

Yi Fang

Department of Endocrinology, Fifth Medical Center of PLA General Hospital, Chinese PLA 307 Hospital, No. 8, East Street, Fengtai District, Beijing 100071, People's Republic of China Tel +86 136 4122 3053 Email fangyi307@163.com



Objective: To evaluate the prognostic factors for cesarean section outcome of pregnant women with diabetes mellitus.

Methods: MEDLINE, EMBASE, Cochrane Library, CBM, CNKI and Wanfang database were searched. Two researchers independently screened the literature, extracted data, and evaluated the risk of bias of included studies. For pooled data with factors of perioperative outcome, the RevMan software was used for data translation and meta-analysis. The result is shown intuitively with the bubble diagram of evidence mapping by Excel 2016.

Results: We included 12 randomized controlled trials (RCTs) in the meta-analysis. Twelve RCTs with 1,390 patients were included in the systematic review. The results show that the perioperative blood glucose management regimens, preoperative fasting and water deprivation, anesthesia regimens, postoperative fluid regimens, postoperative analgesia regimens, postoperative wound care regimens, psychological interventions, different dosing regimens for antibiotics, and obesity may affect the cesarean section outcome of diabetic mothers and newborns. The evidence for all the outcomes was low quality.

Conclusion: Many prognostic factors have shown significant association with postoperative outcomes of cesarean section. More clinical research evidence with high-quality is needed. **Keywords:** gestational diabetes mellitus, caesarean section, prognostic factors, systematic review, meta-analysis, evidence mapping

Background

In pregnant women with gestational diabetes mellitus (GDM), the overall cesarean section rate was accounted for 35.3%.¹ Simultaneously, compared with nondiabetic pregnant women, diabetic maternal acute cesarean section rate was reported 1.52 times of GDM.² Diabetes is an important risk factor for surgical incision infection,³ and for cesarean section, diabetes is an important risk factor for maternal post-operative wound infection as well.⁴ Thus, the pregnancy with diabetes and the management of special risk factors are important, and the existing systematic evaluation shows that effective treatment and control of GDM can reduce preeclampsia, shoulder dystocia, and the incidence of huge children.⁵ In addition, several systematic reviews have concentrated on the effects of certain specificc factors based on the health outcomes of pregnant women with GDM, such as the effects of different glycemic management regimens on glycemic control and maternal and child outcomes,^{6–10} and effects of dietary intervention or nutritional

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2019:12 913–929 913 © 2019 Wang et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. by and licenserate the Creative Commons Attribution – Non Commercial (unported, vi.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). therapy based on maternal and child outcomes.^{11,12} For patients with cesarean section with GDM, there have been several studies evaluating differences in patients' outcomes under different conditions, such as anesthesia,^{13–15} postoperative fluid regimen,^{16,17} and postoperative wound care.¹⁸ However, there is no systematic review regarding the current evaluation of the factors affecting the maternal and child's outcomes during the period of affecting by GDM. This study was designed to assess the risk factors associated with perioperative outcomes in pregnant women with GDM.

Methods

Inclusion and exclusion criteria

Inclusion criteria: 1) pregnant women suffered cesarean section with GDM; 2) exposure factors for cesarean outcomes; 3) RCTs; and 4) reported perioperative outcomes, such as blood glucose level, Apgar scores, adverse effects, and so on. Exclusion criteria: 1) there were no specific outcome data to assess the impact of exposure factors on patients with perioperative outcomes; 2) non-English and Chinese published research, 3) summary of unpublished meeting.

Literature search

We conducted a systematic search on Medline (via PubMed), EMBASE, Cochrane Library, CBM, CNKI and Wanfang, using the terms Diabetes, Gestational, Diabet*, "Cesarean Section", caesarean, "diabetes, pregnancy", "gestational diabetes mellitus", "cesarean section", "cesarean section", "cesarean section", "cesarean section". The retrieval date was February 28, 2018.

Study screening

Two researchers independently screened the literature titles, abstracts, and the full text. A pre-test was performed prior to formal screening of the literature to ensure that each researcher truly perceived the screening criteria and process. Discrepancies between the two reviewers were resolved by consensus discussion.

Data extraction

The two researchers independently extracted the following data from the pre-designed information extraction table: year of publication, name of journal, the first author's affiliation, place and duration of study, funding, conflict of interest, type of study, sample size, basic characteristics of study object, exposure factors, and associated outcome data. A pretest was conducted before formal extraction to ensure that each researcher agrees with the extraction criteria and process. If there are some differences, they could be solved through discussion.

Risk of bias assessment

Two researchers used the Cochrane risk of bias tool was used for bias risk assessment of randomized controlled trials. A pretest was conducted before the formal evaluation to ensure that each researcher agrees with the evaluation criteria and process. In case of existence of some differences, they could be solved by a third researcher.

Data consolidation and analysis

In the RevMan 5.3 software, the RR and 95% CI were used to combine the binary data, and the data were merged using the mean difference (MD) and 95% CI. The data combination uses a random-effect model. The heterogeneity was included in the study by Cochran's Q test (P < 0.05 denotes heterogeneity) and I^2 test. When the number of inclusion indicators is ≥ 10 , the publication bias is evaluated by making a funnel plot; conversely, the qualitative analysis was included in the study funding, the conflict of interest, and the outcome to discuss the possibility of publication bias.

Quality of evidence

The quality of the evidence was graded according to the principles of the GRADE approach used in the evaluation of prognostic studies^{19,20} and in a previous study (as example).²¹ (These factors may lead to rating down the quality of evidence in GRADE system) and the three upgraded factors (large effect, dose-response, and plausible confounders) to determine the final level of evidence. Quality of evidence was ranked as high, medium, low, and very low-level using the results of summary table.

Evidence mapping

Excel 2016 was used to integrate the RR value from metaanalysis and GRADE. The result is shown intuitively with the bubble diagram. Due to heterogeneity of MD for the outcome, we did not make a bubble diagram for MD value from meta-analysis.

Results

Study selection

There are 13,447 articles identified by literature search. After duplicates were removed in endnote, 11,585 records titles and abstractswere reviewed, 142 articles were retrieved full-text reviewing. Finally, a total of 12 randomized controlled trials^{14,16–18,22–29} involving 1,390 patients were included for meta-analysis (Figure 1).

Characteristics of the included studies

The studies were published in 2010 and 2017, the sample sizes ranged from 33 to 201. All studies were from China. The participant age was from 24 to 39. The two studies^{16,23} were funded by nonprofit funds, one study reported that there was not the conflict of interest, and the rest of the study did not report funding (Table 1).

Risk of bias for included studies

The included RCTs were only low risk of bias in incomplete outcome data and selective reporting (Figure 2); 8 studies^{14,17,18,24–26,29} did not report random sequences; 1

study²⁷ reported that there was a high risk of bias in random sequences; none of the studies reported allocation concealment; 6 studies^{16,18,26–29} did not blind the researchers and patients, and they likely contained an impact on the results; 8 studies^{14,18,22–26,29} did not blind the outcome evaluators, and they likely contained an influence on the results.

Prognostic factors

Insulin pump

One randomized controlled study²⁵ reported a total of 3 outcomes. It was revealed that duration of treatment process (MD=-5.30, 95% CI: -5.78~-4.82, P<0.00001), insulin dosage (MD=17.00, 95% CI: -23.04~-10.96, P<0.00001), and the incision healing duration (MD= -4.40, 95% CI: -5.58~-3.22, P<0.00001) of the repeated subcutaneous injection for insulin group were superior to those of the insulin pump group, and the difference was statistically significant (Appendix 1).

Short-term fasting and water deprivation

One randomized controlled study²⁷ reported a total of 11 outcomes. Preoperative blood glucose concentrations




Figure I The screening flow chart.

Age mp Range: 24-36 m fasting 24-36 n 24-36 on 24-36 on 24-36 n 24-36 on 24-36 on 24-36 n 23-91 n 23-91 n 23-91 n 23-36 n 24-36 e 24-36 e 24-36 e 24-36 o 1njection o 18 bost- 25.13 on 25.13 on <td< th=""><th>Time of Sample Progno: research size factors</th><th>stic</th><th>Exposed group (Mean±SD)</th><th>4ean±SD)</th><th>Nonexpose ±SD)</th><th>Nonexposed group (Mean ±SD)</th></td<>	Time of Sample Progno: research size factors	stic	Exposed group (Mean±SD)	4ean±SD)	Nonexpose ±SD)	Nonexposed group (Mean ±SD)
2010China \circ \circ $2007.1-2009.12$ 48Insulin pumpRange: 24-3622017China \circ \circ $2015.4-2015.9$ 162Short-term fasting32.9122017China \circ \circ $2015.4-2016.2$ 110Individual health \circ 22017China \bullet \circ $2014.1-2016.2$ 110Individual health \circ 22010China \bullet^* \circ $200.2-2010.3$ 70Fructose Injection \circ 22010China \bullet^* \circ $2011.3-201.7$ 33PCEA 237 22011China \circ \circ $2011.3-201.3$ 70Fructose Injection \circ 22014China \circ \circ $2011.3-201.3$ 140Microwave trat 24.5 22014China \circ \circ $2011.3-201.3$ 201Fructose Injection 31.8 22014China \circ \circ $2011.3-201.3$ 140Microwave trat 26.4 22015China \bullet^* \circ $2012.3-201.31$ 140Microwave trat 25.13 22015China \bullet^* \circ $2012.3-201.31$ 150Pychological 25.13 22015China \bullet^* \circ $2012.3-201.31$ 99Pychological 25.13 22015China \bullet^* \circ $2014.3-201.31$ 99Pychological 25.13 22015 <th></th> <th>Ř</th> <th>ge Weight (kg)</th> <th>Gestation (weeks)</th> <th>Age Wei (kg)</th> <th>Weight Gestation (kg) (weeks)</th>		Ř	ge Weight (kg)	Gestation (weeks)	Age Wei (kg)	Weight Gestation (kg) (weeks)
7 201 1	48			0	Range: 0 24~36	0
2017China \circ \circ 2014.1-2016.2110Individual health \circ 2010China \bullet^a \circ 2009.2-2010.370Fructose Injection \circ 2011China \circ^a \circ 2009.2-2013.370Fructose Injection 297 2014China \circ \circ $2011.3-2011.7$ 33PCEA 297 2014China \circ \circ $2011.5-2013.0$ 201Fructose Injection 31.8 2015China \circ \circ $2012.9-2013.9$ 140Microwave treat- 26.4 2015China \circ \circ $2012.9-2013.9$ 140Microwave treat- 25.4 2015China \circ \circ $2012.9-2013.1$ 153Pychological 27.9 2015China \bullet^b \circ $2012.9-2013.1$ 153Pychological 27.9 2015China \bullet^b \circ $2014.3-2015.3$ 24Epidural anesthesia 28.1 42015China \circ \circ $2014.3-2015.3$ 24Epidural anesthesia 26.1 42015China \circ \circ $2014.3-2015.3$ 24E	162	fasting		38.74±1.54	4.07 ○ ±4.39	38.28±1.47
2010China \bullet^* \circ 2009.2-2010.370Fructose Injection \circ 2011China \circ \circ 2011.3-2011.733PCEA29.729.72014China \circ \circ 2011.5-2013.10201Fructose Injection31.829.72015China \circ \circ 2011.5-2013.10201Fructose Injection31.829.72015China \circ \circ 2011.5-2013.10201Fructose Injection31.82015China \circ \circ 2012.2-2014.1153PSychological25.132015China \bullet^b \circ 2012.2-2014.1153PSychological25.132015China \bullet^b \circ 2012.2-2014.1153PSychological25.132015China \bullet^b \circ 2012.2-2014.1153Psychological25.132015China \bullet^b \circ 2014.3-2015.3240Psychological30.052015China \bullet^b \circ 2014.3-2015.354Epidural anesthesia28.12015China \circ \circ 2014.3-2015.354Epidural anesthesia28.12015China \circ \circ 2012.3-2013.1299Low dose sufenca30.72015China \circ \circ 2012.3-2013.1299Low dose sufenca20.72015China \circ \circ 2012.3-2013.1299Low dose sufenca20.72015 <td>0</td> <td></td> <td>0</td> <td>0</td> <td>0</td> <td>0</td>	0		0	0	0	0
2011China \circ \circ $2011.3-2011.7$ 33PCEA 29.7 2014China \circ \circ $2011.5-2013.10$ 201 Fructose Injection 31.8 2015China \circ \circ $2011.5-2013.9$ 140 Microwave treat- 26.4 2015China \circ \circ $2012.9-2013.9$ 140 Microwave treat- 26.4 2015China \circ \circ $2012.2-2014.1$ 153 Psychological 25.13 2015China \circ \circ $2012.2-2014.1$ 153 Psychological 25.13 2015China \bullet^b \circ $2012.2-2014.1$ 153 Psychological 25.13 2015China \bullet^b \circ $2014.1-2015.5$ 200 Psychological 25.13 2015China \circ^b \circ $2014.1-2015.3$ 200 Psychological 25.13 2015China \circ^b \circ $2014.3-2015.3$ 54 Epidural anesthesia 281 2015China \circ \circ \circ $2014.3-2015.3$ 54 Epidural anesthesia 207 2015China \circ \circ 0 0 0 0 <td>70</td> <td></td> <td>0</td> <td>0</td> <td>0</td> <td>0</td>	70		0	0	0	0
2014China002011.5-2013.10201Fructose Injection31.82015China002012.9-2013.9140Microwave treat-26.42015China002012.9-2013.9140Microwave treat-26.42015China002012.2-2014.1153Psychological25.132015China002012.2-2014.1153Psychological25.132015China002014.1-2015.5200Psychological25.1342015China002014.3-2015.3240Psychological25.1342015China002014.3-2015.354Epidural anesthesia28.142015China002014.3-2015.354Epidural anesthesia28.142015China002014.3-2015.354Epidural anesthesia28.142015China002012.3-2013.1299Low dose suffente-26.142015China002012.3-2013.1299Low dose suffente-26.142015China002012.3-2013.1299Low dose suffente-20.742015China002012.3-2013.1299Low dose suffente-20.742015China002012.3-2013.1299Low dose suffente-20.74 <td< td=""><td>33</td><td></td><td>7 76.7±6.3 .7</td><td>0</td><td>30.1 77.5 ±4.1</td><td>77.2±6.2 o</td></td<>	33		7 76.7±6.3 .7	0	30.1 77.5 ±4.1	77.2±6.2 o
2015China \circ \circ $2012.9-2013.9$ 140Microwave treat- 26.4 12 2015 2015 $2012.2-2014.1$ 153Psychological 25.13 12 2015 China \circ \circ $2012.2-2014.1$ 153Psychological 25.13 12 2015 China \bullet^{b} \circ $2014.1-2015.5$ 200 Psychological 25.13 12 2015 China \bullet^{b} \circ $2014.1-2015.5$ 200 Psychological 30.5 12 China \bullet^{b} \circ $2014.1-2015.5$ 200 Psychological 30.5 12 China \bullet^{b} \circ $2014.1-2015.5$ 200 Psychological 30.5 12 China \bullet^{b} \circ $2014.1-2015.3$ 240 Psychological 30.5 13 China \circ \circ $2014.3-2015.3$ 54 Epidural anesthesia 28.1 12 China \circ \circ $2014.3-2015.12$ 99 Low dose sufenta- 30.7 12 China \circ \circ $2012.3-2013.12$ 99 Low dose sufenta- 30.7 12 China \circ \circ $2012.3-2013.12$ 99 Low dose sufenta- 30.7 12 China \circ \circ $2012.3-2013.12$ 99 Low dose sufenta- 30.7 12 China \circ \circ $2012.3-2013.12$ 99 Low dose sufenta- 30.7 12 Ch	201			38.8±1.9	31.8 ⊃ ±6.9	38.8±1.9
20 2015 China \circ \circ $2012.2 \sim 2014.1$ 153 Psychological 25.13 2015China \bullet^{b} \circ $2014.1 \sim 2015.5$ 200 Psychological 25.24 2015China \bullet^{b} \circ $2014.1 \sim 2015.5$ 200 Psychological 20.5 42015China \bullet^{b} \circ $2014.3 \sim 2015.3$ 54 Epidural anesthesia 28.1 42015China \circ \circ $2014.3 \sim 2015.3$ 54 Epidural anesthesia 28.1 5China \circ \circ $2012.3 \sim 2013.12$ 99 Low dose sufenta- 30.7 2015China \circ \circ $2012.3 \sim 2013.12$ 99 Low dose sufenta- 24.1 2015China \circ \circ $2012.3 \sim 2013.12$ 99 Low dose sufenta- 27.1 2017China \circ \circ $2016.2 \sim 2017.6$ 120 Addition of once 27.2	140	<u>ب</u> ک		0	26.4 o ±2.9	0
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	153			26.05±0.23	25.13 ○ ±5.24	26.05±0.23
5^{14} 2015China \circ \circ $2014.3 \sim 2015.3$ 54 Epidural anesthesia 28.1 5.4 2015 \circ \circ $2014.3 \sim 2013.12$ 99 Low dose sufenta- 30.7 10^{20} China \circ \circ $2012.3 \sim 2013.12$ 99 Low dose sufenta- 30.7 10^{20} China \circ \circ $2012.3 \sim 2013.12$ 99 Low dose sufenta- 30.7 10^{729} China \circ \circ $2012.3 \sim 2017.6$ 120 Addition of once 27.2	200			0	29.03 ○ ±1.56	0
2015 China o 2012.3~2013.12 99 Low dose sufenta- 30.7 1000 1000 1000 1000 1000 1000 1000 1017 ²⁹ 2017 China 0 2016.2~2017.6 120 Addition of once 272	54			37.9±5.I	29.0 ○ ±5.4	38.5±5.4
2017 China 0 2016.2~2017.6 120 Addition of once 27.2	66		7 78.2±8.1 .1	37.8±1.0	30.2 77.3 ±2.0	77.7±7.3 38.1±0.9
antibiotic ±3.25	120	of once		0	29.1 ○ ±4.03	0

Table I Basic characteristics of included studies

916




Figure 2 Risk of bias graph.

(MD=0.84, 95% CI: 0.42~1.26, P=0.001) and the level of blood glucose in newborn infants after birth (MD=0.45, 95% CI: -0.03~0.87, P=0.038) for short-term group were superior to those of long-term group, and the difference was statistically significant. Bleeding volume during cesarean section (MD=-42.71, 95% CI:-82.55~-2.86, P=0.039) for short-term group was inferior to long-term group, and the difference was statistically significant. There were no significant differences in postoperative blood sugar concentrations, the rates of nausea and vomiting, incidence of hypoglycemia in newborn infants after birth and mothers before cesarean section, duration of anus exhausting of puerpera, Apgar score 1 and 5 mins after delivery (Appendix 1).

Individual health education

A randomized controlled study²⁸ reported a total of 4 outcomes. Control rates for 2 hr plasma glucose (PG) (RR=1.31, 95% CI: 1.04~1.66, P<0.05) and midnight blood glucose (RR=1.23, 95% CI: 1.01~1.50, P<0.05) and the satisfaction rate of nursing services (MD=6.51, 95% CI: 5.80~7.22, P<0.01) for individualized health education group were superior to those of conventional health education group, and the difference was statistically significant. There were no significant differences in control rates of fasting blood glucose (FBG) as well (Appendix 1).

Fructose injection

Two randomized controlled trials^{16,17} reported a total of 8 outcomes. The blood glucose levels 1.5–2 hours after infusion (MD=–1.17, 95% CI: –1.93~–0.41, P=0.003), blood glucose levels 3–4 hours after infusion (MD=–0.99, 95% CI: –1.61–0.36, P=0.002), the level of insulin 1.5 hours after

infusion (MD=-13.50, 95% CI: $-19.02 \sim 7.98$) (*P*<0.00001), and the level of insulin 3 hours after infusion (MD=-8.59, 95% CI: $-13.75 \sim -3.43$, *P*=0.001) for fructose injection were superior to glucose and Insulin injection. The difference was statistically significant. There were no significant differences in blood glucose level, blood glucose level, urinary carcass positive rate, and urine sugar positive rate after transfusion, and no significant difference was found between the two groups (Appendix 1).

Patient-controlled epidural analgesia (PCEA)

A randomized controlled trial²⁴ reported a total of 13 outcomes. The level of blood glucose in presence of analgesia after 6 hours (MD=-0.80, 95% CI: -1.01 to -0.59, P<0.00001), 12 hours (MD=-0.76, 95% CI: -1.00 to -0.52, P<0.00001), 24 hours (MD=-0.65, 95% CI: -0.87to -0.43, P<0.00001), and 36 hours (MD=-0.75,95% CI: $-0.96\sim-0.54$, P<0.00001) for the patient-controlled intravenous analgesia (PCIA) group was superior to PCIA group. The difference was statistically significant. There was no significant difference between the two groups (Appendix 1).

Microwave treatment for postoperative wound

A randomized controlled trial¹⁸ reported a outcome (RR=1.15, 95% CI: 1.03~1.29, P=0.01, see Appendix 1, in which the difference was statistically significant (P<0.01) (Appendix 1).

Psychological intervention (including music therapy)

Two randomized controlled trials^{22,23} reported a total of 14 outcome indicators, in addition to entering the operating room immediately with heart rate (MD=-0.86, 95% CI: $-2.69\sim0.97$, *P*=0.36), entering the operating room immediately with anxiety score (MD=-0.13, 95%

CI: $-2.57 \sim 2.31$, P=0.92), and the normal feeding rate (RR=1.07, 95% CI: 0.99–1.16, P=0.09). The difference between the two groups was not statistically significant. The rest of the outcome indicators for the psychological intervention group were inferior to the conventional nursing group, and the difference between the two groups was statistically significant (Appendix 1).

Epidural anesthesia

A randomized controlled trial¹⁴ reported a total of six outcomes: glucose concentration at the of cutting skin (MD=1.48, 95% CI: 1.31~1.65, P<0.00001, 2 hours after delivery (MD=0.90, 95% CI: 0.71 to 1.09, P<0.00001) and 6 hours after delivery (MD=1.11, 95% CI: 0.93 to 1.29, P<0.00001), the epidural group were higher than the general anesthesia group, and the difference was statistically significant. The differences in the other outcomes between the two groups were not statistically significant (Appendix 1).

Low-dose sufentanil combined with bupivacaine of spinal-epidural anesthesia

One randomized controlled study²⁶ reported a total of 11 outcomes. Based on the report, glucose concentration at the time of cutting skin (MD=–1.45, 95% CI: –1.61~–129, P<0.00001), the blood glucose concentration 2 hours after delivery (MD=–0.89, 95% CI: –1.07~–071, P<0.00001), and the mean arterial pressure 5 mins after anesthesia (MD=5.80, 95% CI: 3.12~8.48, P<0.00001) were assessed. The difference was statistically significant. However, the differences for the other outcome indicators between the two groups were not statistically significant (Appendix 1).

Addition of once antibiotic

One randomized controlled study²⁹ reported a total of 12 outcomes. The treatment efficiency (RR=0.68, 95% CI: $0.04\sim1.66$, P<0.05) of the addition of an antibiotic once group was inferior to 24 hours antibiotic application group, and the difference was statistically significant. There were no significant differences in response rate, overall response rate, the inefficiency rate, the duration of WBC <12×10⁹/L, body temperature (without fever or returned to normal status 2 hours after surgery), and the grades A, B, and C of healing (Appendix 1).

Publication bias

The number of studies included in every outcome was <10; thus, it was unattempted to use funnel plot to assess the publication bias. All studies have not reported conflict

of interest, and only 2 studies reported that the funding originated from the nonprofit grants.

Quality of evidence

The levels of evidence for all the outcome all is low on the GRADE system (see Appendix 2). The reasons for downgrading includes the risk of bias (no randomized sequence generation and allocation concealment, no blindness to researchers, patients and outcome evaluators) and inaccuracy (sample size is less than the optimal sample size and the confidence interval of the combined results cross invalid line).

Evidence mapping

Each bubble corresponds to one outcome for the prognostic factors. The size, color, and position of the bubbles were used to indicate the current research status. The size of the bubbles indicates the sample size, and the color of the bubbles indicates the quality of the evidence. The horizontal coordinate indicates the prognostic factors, the vertical coordinate indicates the RR of meta-analysis (Figure 3).

Discussion

The International Federation of Gynecology and Obstetrics (FIGO) guideline recommended to receive cesarean section to prevent shoulder dystocia or birth injury, when fetal weight would be>4,000 g.³⁰ For pregnant women with cesarean section, in addition to the conventional perinatal management, the integration of perioperative management is required, including blood sugar control, anesthesia, healthcare, etc. This study is the first systematic review of the prognostic factors. The results of the systematic review show that the perioperative blood glucose management regimens, preoperative fasting and water-deprivation regimens, anesthesia regimens, postoperative regimens, postoperative analgesia regimens, postoperative wound care regimens, psychological interventions, and different dosing regimens for antibiotics may affect the health outcomes of diabetic maternal and newborns. However, the quality of evidence was low, and more high-quality clinical research evidence is required.

According to the principle of GRADE method in the evaluation of a prognosis research system,^{10,11} the quality of evidence for each outcome is low, and the reason of downgrading is mainly bias risk and inaccuracy. The bias risks included in the randomized controlled trials were assessed by the Cochrane Bias Risk Assessment Tool, in




Figure 3 Summary of risk ratio and quality of evidence of outcomes for the prognostic factors with the bubble diagram. Abbreviation: PCEA, patient-controlled epidural analgesia.

which the main source of bias was the nonreported random sequence generation and allocation concealment, which did not blind the researchers, the patients, and the outcome evaluators, and did not report the source of the information and the method of recruiting or joining the patients. The reason for the imprecision is that the sample size is less than the optimal sample size, and the CI of the effect sizes spans the invalid line. For publication bias, as the number of included studies was <10, the publication bias was not evaluated using a funnel plot. In addition, the included studies did not report the conflict of interest, considering the research topics and manufacturers that may be the interests of the relationship, and in addition to psychological intervention and obesity factors, the rest of the comparison groups were assessed by the possibility of publication bias. However, it was not possible to quantify the possibility of publication bias; thus, the publication bias was not considered in this study. In addition, because most of outcomes included only 1 study, a few outcomes included only 2 studies, and I² values are small, it is not been downgraded due to heterogeneity. We performed

meta-analyses by using the random effects model for multiple risk factors and outcomes. The qualities of the evidence for all outcomes were low. As the number of studies increases and the quality of the research improves, new research data may change the results of this system review. Therefore, it needs to more new high-quality research to update the review in the future.

The main advantages of this systematic review are: 1) for the first time on the impact of pregnancy in patients with diabetes maternal-perinatal outcome of the perioperative factors were evaluated; 2) the original research carried out a systematic, comprehensive search, greatly reducing the possibility of missing; 3) the quality of evidence was graded by GRADE method, and the factors affecting the outcome of perioperative period of cesarean section in pregnant women with diabetes mellitus were clearly presented and interpreted. The limitations of the system review: 1) Only the studies published in Chinese and English were searched, the other languages were not be considered; 2) All the studies are from China, the results may not been applied to other countries and regions.

Conclusion

Low-quality evidence shows that perioperative blood glucose management regimens, anesthesia regimens, postoperative fluid regimens, postoperative analgesia regimens, postoperative wound care, and psychological interventions may affect the health outcomes of diabetic maternal and newborns.

Details of ethics approval

No ethics approval was required or sought for this review.

Data sharing statement

This review does not involve any analysis of individual patient data.

Acknowledgment

This review was supported by Beijing Municipal Science and Technology Commission (Project no. D141107005314004).

Disclosure

The authors report no conflicts of interest in this work.

References

- Goldman M, Kitzmiller JL, Abrams B, Cowan RM, Laros RK. Obstetric complications with GDM. *Diabetes*. 1991;40(Suppl 2):79–82.
- Gorgal R, Gonçalves E, Barros M, et al. Gestational diabetes mellitus: a risk factor for non-elective cesarean section. J Obstet Gynaecol Res. 2012;38(1):154–159. doi:10.1111/j.1447-0756.2011.01659.x
- Martin ET, Kaye KS, Knott C, et al. Diabetes and risk of surgical site infection: a systematic review and meta-analysis. *Infect Control Hosp Epidemiol.* 2016;37(1):88–99. doi:10.1017/ice.2015.249
- 4. Leth RA, Uldbjerg N, Nørgaard M, Møller JK, Thomsen RW. Obesity, diabetes, and the risk of infections diagnosed in hospital and post-discharge infections after cesarean section: a prospective cohort study. Acta Obstet Gynecol Scand. 2011;90(5):501–509. doi:10.1111/ j.1600-0412.2011.01090.x
- Hartling L, Dryden DM, Guthrie A, Muise M, Vandermeer B, Donovan L. Benefits and harms of treating gestational diabetes mellitus: a systematic review and meta-analysis for the U.S. Preventive Services Task Force and the National Institutes of Health Office of Medical Applications of Research. *Ann Intern Med.* 2013;159(2):123–129. doi:10.7326/0003-4819-159-2-201307 160-00661
- Nicholson W, Bolen S, Witkop CT, Neale D, Wilson L, Bass E. Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review. *Obstet Gynecol.* 2009;113 (1):193–205. doi:10.1097/AOG.0b013e318190a459
- Amin M, Suksomboon N, Poolsup N, Malik O. Comparison of glyburide with metformin in treating gestational diabetes mellitus: a systematic review and meta-analysis. *Clin Drug Investig.* 2015;35 (6):343–351. doi:10.1007/s40261-015-0289-3

- González Blanco C, Chico Ballesteros A, Gich Saladich I, Corcoy Pla R. Glycemic control and pregnancy outcomes in women with type 1 diabetes mellitus using lispro versus regular insulin: a systematic review and meta-analysis. *Diabetes Technol Ther*. 2011;13(9):907–911. doi:10.1089/dia.2011.0032
- Lv S, Wang J, Xu Y. Safety of insulin analogs during pregnancy: a meta-analysis. Arch Gynecol Obstet. 2015;292(4):749–756. doi:10.1007/s00404-015-3692-3
- Zeng YC, Li MJ, Chen Y, et al. The use of glyburide in the management of gestational diabetes mellitus: a meta-analysis. *Adv Med Sci.* 2014;59(1):95–101. doi:10.1016/j.advms.2014.03.001
- 11. Viana LV, Gross JL, Azevedo MJ. Dietary intervention in patients with gestational diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials on maternal and newborn outcomes. *Diabetes Care.* 2014;37(12):3345–3355. doi:10.2337/dc14-1530
- Thomaz de Lima H, Lopes Rosado E, Ribeiro Neves PA, et al. Systematic review; Nutritional therapy in gestational diabetes mellitus. *Nutr Hosp.* 2013;28(6):1806–1814. doi:10.3305/nutrhosp. v28in06.6892
- Datta S, Brown WU Jr. Acid-base status in diabetic mothers and their infants following general or spinal anesthesia for cesarean section. *Anesthesiology*. 1977;47(3):272–276.
- 14. Yin X. The clinical effectiveness of different methods of anesthesia for the puerperants with gestational diabetes mellitus. *Chin J Mod Drug Appl.* 2015;9(17):128–130. Chinese.
- 15. Zheng W, Huang X. The analysis of hypopiesia led by different options of anesthesia for the patients with gestational diabetes mellitus in cesarean section. *Contemp Med Forum*. 2015;13(16):221–222. Chinese.
- Wang X, Jin Z, Xu Q, et al. Effects of fructose on metabolic changes after cesarean section in gestational diabetes mellitus patients. *Chin J Pract Gynecol Obstet.* 2010;26(12):933–935. Chinese.
- 17. Yu R. The effect of fructose in fusion on the levels of blood glucose and insulin in gestationai diabetes mellitus patients after cesarean section. *Strait Pharm J.* 2014;26(12):102–105. Chinese.
- Chen H. The analysis of effectiveness of microwave therapy for surgical site healing in the puerperae with diabetes. *Henan Med Res.* 2015;24(11):76–77. Chinese.
- Huguet A, Hayden JA, Stinson J, et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. *Syst Rev.* 2013;2:71. doi:10.1186/2046-4053-2-71
- 20. Iorio A, Spencer FA, Falavigna M, et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. *BMJ*. 2015;350:h870. doi:10.1136/bmj.h870
- Goldsmith R, Wright C, Bell SF, Rushton A. Cold hyperalgesia as a prognostic factor in whiplash associated disorders: a systematic review. *Man Ther.* 2012;17(5):402–410. doi:10.1016/j.math.2012. 02.014
- 22. Han M. The applying of psychological interventions for the patients with gestational diabetes mellitus in peri-operative period. *Chin J Prim Bled Pharm*. 2015;22(5):757–759. Chinese.
- 23. Li D, Liu Z, Xu P, et al. The effect of music therapy for anxiety and hemodynamics of gestational diabetes mellitus patients with cesarean section. *J Hebei Med Univ.* 2015;36(12):1464–1466. Chinese.
- 24. Zhao L, Zhai J, Shen X. The effect of two analgesia options on the blood sugar of gestational diabetes mellitus patients with cesarean section. *Shanghai Med J.* 2011;34(12):955–956. Chinese.
- 25. Li N, Zhang H, Jiang S. The effectiveness of peri-operative insulin pump on the patients with gestational diabetes mellitus. *Chin J Misdiagn.* 2010;10(12):2845–2846. Chinese.
- 26. Zhang Y, Zhao Y, Zhao E, et al. The effectiveness of small dose of sulfentanyl combining with bupivacaine on cesarean section in the puerperants with gestational diabetes mellitus. *China Pharm.* 2015;24 (1):9–10. Chinese.

- 27. Feng J, Bao A, Lu Y, et al. Effects of preoperative fasting and liquid-fasting time before caesarean section on blood glucose of puerperae with GDM and neonates. *Chin J Mod Nurs.* 2017;23 (4):509–512. Chinese.
- 28. Wang T, Miao P, Hu J. Effects of individualized health education on blood glucose after cesarean section in diabetes mellitus with pregnancy. *Contemp Med.* 2017;23(27):168–170. Chinese.
- 29. Yang G, Abulaiti Z, Qian Y, et al. Effect comparison of different antibiotic regimens in the prevention infection after cesarean in patients with gestational diabetes mellitus. *Xinjiang Med J.* 2017;47(4):366–368.
- 30. Hod M, Kapur A, Sacks DA, et al. The International Federation of Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes mellitus: A pragmatic guide for diagnosis, management, and care. *Int J Gynaecol Obstet.* 2015;131(Suppl 3):S173–S211. doi:10.1016/ S0020-7292(15)30033-3

Supplementary materials

Appendix 1. Effect evaluation results

Outcome	No. of studies	No. of participants	Effect estimate RR/MD (95%CI)	P value
Insulin pump VS multiple subcutaneous injections of insulin				
Blood glucose standard time (d)	1	48	MD: -5.30 (-5.78, -4.82)	<0.00001
Dose of insulin (U/d)		48	MD: -17.00 (-23.04,	<0.00001
		10	-10.96)	-0.00001
Surgical incision healing time /d	1	48	MD: -4.40 (-5.58, -3.22)	<0.00001
Fasting and water-deprivation: short-term VS long-term				
Preoperative blood glucose (mmol/L)	I	162	MD: 0.84 (0.42, 1.26)	0.001
Postoperative blood glucose(mmol/L)	1	162	MD: 0.16 (-0.17, 0.49)	0.345
Incidence of nausea	1	162	RR: 2.98 (0.77, 11.51)	0.180
Incidence of vomiting	1	162	RR: 2.24 (0.38, 13.03)	0.647
Incidence of neonatal hypoglycemia	1	162	RR: 0.25 (0.03, 2.02)	0.302
Incidence of preoperative hypoglycemia	1	162	RR: 0.54 (0.18, 1.63)	0.264
Maternal anal discharge time(h)	1	162	MD: -0.04 (-0.25, 0.17)	0.692
Bleeding during childbirth (ml)	1	162	MD: -42.71 (-82.55, -2.86)	0.039
Neonatal Apgar scores at 1 min	1	162	MD: 0.03 (-0.18, 0.24)	0.918
Neonatal Apgar scores at 5 min	1	162	MD: -0.03 (-0.14, 0.08)	0.183
Postnatal blood glucose (mmol/L)	I	162	MD: 0.45 (0.03, 0.87)	0.038
Health education: individualization VS convention				
Fasting blood glucose compliance rate	I	110	RR: 1.08 (0.86, 1.35)	>0.05
Glucose-target-rate at 2 o'clock	1	110	RR: 1.31 (1.04, 1.66)	<0.05
Glucose-target-rate at 0 o'cl	1	110	RR: 1.23 (1.01, 1.50)	<0.05
Nursing service satisfaction	1	110	MD: 6.51 (5.80, 7.22)	<0.01
Fructose Injection VS Glucose Injection + Insulin	-			
Blood glucose level at 1.5~2h after infusion (mmol/L)	2	202	MD: -1.17 (-1.93, -0.41)	0.003
Blood glucose level at 3~4h after infusion (mmol/L)	2	202	MD: -0.99 (-1.61, -0.36)	0.002
Blood glucose level at 6h after infusion (mmol/L)	1	70	MD: -0.62 (-1.86, 0.61)	0.32
Insulin level at 1.5h after infusion (mU/L)	1	132	MD: -13.50 (-19.02, -7.98)	<0.00001
Insulin level at 3h after infusion (mU/L)	1	132	MD: -8.59 (-13.75, -3.43)	0.001
Blood uric acid level at 3h after infusion (μ mol/L)	1	132	MD: -8.00 (-34.96, 18.96)	0.56
Positive rate of urine carcass	2	202	RR: 1.14 (0.49, 2.64)	0.77
Positive rate of urine glucose	I	70	RR: 0.21 (0.01, 4.25)	0.31
PCEA VS PCIA				
Blood glucose level at 3h after the onset of analgesia (mmol/L)	I	33	MD: 0.01 (-0.21, 0.23)	0.93
Blood glucose level at 3h after the onset of analgesia (mmol/L)	1	33	MD: -0.80 (-1.01, -0.59)	<0.00001
Blood glucose level at 12h after the onset of analgesia (mmol/L)	1	33	MD: -0.76 (-1.00, -0.52)	<0.00001
Blood glucose level at 24h after the onset of analgesia (mmol/L)	1	33	MD: -0.65 (-0.87, -0.43)	<0.00001
Blood glucose level at 36h after the onset of analgesia (mmol/L)	1	33	MD: -0.75 (-0.96, -0.54)	<0.00001
VAS score at 36h after the onset of analgesia (mmol/L)	1	33	MD: -0.04 (-0.31, 0.23)	0.77
VAS score at 6h after the onset of analgesia (mmol/L)	1	33	MD: -0.01 (-0.20, 0.18)	0.92
VAS score at 12h after the onset of analgesia (mmol/L)	1	33	MD: -0.02 (-0.24, 0.20)	0.86
VAS score at 24h after the onset of analgesia (mmol/L)	1	33	MD: -0.05 (-0.39, 0.29)	0.77
VAS score at 36h after the onset of analgesia (mmol/L)	1	33	MD: -0.04 (-0.35, 0.27)	0.80

Outcome	No. of studies	No. of participants	Effect estimate RR/MD (95%CI)	P value
Satisfaction rate of analgesic effect	1	33	RR: 1.00 (0.89, 1.12)	1.00
Vausea and vomiting	1	33	RR: 0.31 (0.01, 7.21)	0.47
Uroschesis	I	33	RR: 2.83 (0.12, 64.89)	0.51
Postoperative wound care: microwave treatment of VS routine care				
Wound healing rate at first stage	I	140	RR: 1.15 (1.03, 1.29)	0.01
Psychological intervention (including music therapy) VS routine care		I		
Systolic pressure immediately into the operating room (mmHg)	I	200	MD: -9.80 (-12.42, -7.18)	<0.0000
Systolic pressure after surgery into the operating room 30min (mmHg)	1	200	MD: -35.37 (-38.32, -32.42)	<0.0000
Intraoperative systolic pressure (mmHg)	1	153	MD: -22.63 (-27.24, -18.02)	<0.0000
Diastolic pressure immediately into the operating room (mmHg)	I	200	MD: -3.58 (-5.20, -1.96)	<0.0000
Diastolic pressure after surgery into the operating room 30min (mmHg)	1	200	MD: -7.58 (-9.62, -5.54)	<0.0000
Intraoperative diastolic pressure (mmHg)	1	153	MD: -10.61 (-14.65, -6.57)	<0.0000
Heart rate immediately into the operating room	I	200	MD: -0.86 (-2.69, 0.97)	0.36
Heart rate after surgery into the operating room 30min	I	200	MD: -8.89 (-10.52, -7.26)	<0.0000
Anxiety score immediately into the operating room	1	200	MD: -0.13 (-2.57, 2.31)	0.92
Anxiety score after surgery into the operating room 30min	I	200	MD: -2.22 (-3.55, -0.89)	0.001
Intro-operative hemorrhage (ml)	1	153	MD: -62.39 (-78.31, -46.47)	<0.0000
Postoperative morbidity	1	153	RR: 0.35 (0.19, 0.64)	0.0008
Postoperative pains	1	153	RR: 0.73 (0.60, 0.89)	0.002
Postoperative normal feeding	I	153	RR: 1.07 (0.99, 1.16)	0.09
Epidural anesthesia vs general anesthesia	•		•	
Blood glucose while skin cutting (mmol/L)	I	54	MD: 1.48 (1.31, 1.65)	<0.0000
Blood glucose while delivery of the fetus (mmol/L)	1	54	MD: 0.00 (-0.17, 0.17)	1.00
Blood glucose while delivery of placenta(mmol/L)	1	54	MD: -0.19 (-0.37, -0.01)	0.04
Blood glucose about 2 hours after delivery of the fetus (mmol/L)	1	54	MD: 0.90 (0.71, 1.09)	<0.0000
Blood glucose about 6 hours after delivery of the fetus (mmol/L)	I	54	MD: 1.11 (0.93, 1.29)	<0.0000
Apgar scores <7	I	54	RR: 0.20 (0.01, 3.98)	0.29
Combined spinal and epidural analgesia: low dose sufentanil combine	ed with bupiva	acaine VS bupivaca	ine	
Blood glucose while skin cutting (mmol/L)	I	66	MD: -1.45 (-1.61, -1.29)	<0.0000
Blood glucose while delivery of the fetus (mmol/L)	1	66	MD: 0.01 (-0.13, 0.15)	0.89
Blood glucose about 5 min after delivery of placenta (mmol/L)	1	66	MD: 0.23 (0.06, 0.40)	0.009
Blood glucose about 2 h after delivery of the fetus (mmol/L)	1	66	MD: -0.89 (-1.07, -0.71)	<0.0000

Appendix 1. (Continued).

Outcome	No. of studies	No. of participants	Effect estimate RR/MD (95%CI)	P value
Mean arterial pressure at 1 min after anesthesia (mmHg)	1	66	MD: 0.40 (-2.11, 2.91)	0.75
Mean arterial pressure at 2 min after anesthesia (mmHg)	1	66	MD: 1.40 (-1.62, 4.42)	0.36
Mean arterial pressure at 5 min after anesthesia (mmHg)	1	66	MD: 5.80 (3.12, 8.48)	<0.00001
Mean arterial pressure at 10 min after anesthesia (mmHg)	1	66	MD: 0.30 (-2.47, 3.07)	0.83
Mean arterial pressure at 20 min after anesthesia (mmHg)	1	66	MD: 1.90 (-1.10, 4.90)	0.21
Apgar score at 1 min	1	66	MD: 0.10 (-0.17, 0.37)	0.46
Apgar score at 5 min	1	66	MD: 0.10 (0.02, 0.18)	0.01
Additional an antibiotic once vs. 24-h antibiotic application				
Marked effective rate	I	120	RR: 0.68 (0.48, 0.97)	<0.05
Effective rate	1	120	RR: 1.50 (0.97, 2.33)	>0.05
Inefficient rate	1	120	RR: 2.00 (0.38, 10.51)	>0.05
Total effective rate	1	120	RR: 0.97 (0.89, 1.05)	>0.05
WBC<12×10 ⁹ /L time (d)	1	120	MD: 0.50 (-0.02, 1.02)	>0.05
Body temperature (no fever and return to normal 48 h after surgery)	1	120	RR: 0.98 (0.93, 1.04)	>0.05
Class-A healing rate	1	120	RR: 0.97 (0.89, 1.05)	>0.05
Class-B healing rate	1	120	RR: 2.00 (0.38, 10.51)	>0.05
Class-C healing rate	1	120	-	>0.05
	1			1

Notes: Bold values indicate statistical significance if the interval does not cross zero for continuous outcomes with MD, and cross one for dichotomous outcomes with RR. The bold values also mean the effect or difference was statistically significant.

Abbreviation: MD, mean difference.

Appendix 2. Summary of Evidence

Outcomes	No of partici- pants(studies)	Quality of the evidence	Relative effect	Anticipated absolute effects	;
	Follow-up	(GRADE)	(95% CI)	Risk with control group	Risk difference with observation group
Insulin pump VS multiple subcuta	neous injections of insuli	n			
Blood glucose standard time (d)	48 (I RCT)	LOW ^{1,2}	-	-	MD 5.3 fewer(5.78
					fewer to 4.82 fewer)
Dose of insulin (U/d)	48 (I RCT)	LOW ^{1,2}	-	-	MD 17 fewer(23.04
					fewer to 10.96
Surgical incision healing time /d	48 (I RCT)	LOW ^{1,2}			fewer) MD 4.4 fewer(5.58
Surgical incision healing time /u			-	-	fewer to 3.22 fewer
Fasting and water-deprivation: she	ort-term VS long-term	1	T	1	1
Preoperative blood glucose	162 (1 RCT)	LOW ^{1,2}	-	-	MD 0.84 more(0.42
(mmol/L)					more to 1.26 more)
Postoperative blood glucose	162 (1 RCT)	LOW ^{1,5}	-	-	MD 0.16 more(0.17
(mmol/L) Incidence of nausea	162 (1 RCT)	LOW 1,5	RR 2.98(0.77	62 per 1,000	fewer to 0.49 more) 15 more per 1,000(61
incidence of nausea	162 (1 KCT)		to 11.51)	62 per 1,000	fewer to 152 more)
Incidence of vomiting	162 (1 RCT)	LOW 1,5	RR 2.24(0.38	21 per 1,000	26 more per 1,000(13
			to 13.03)		fewer to 248 more)
Incidence of neonatal	162 (1 RCT)	LOW 1,5	RR 0.25 (0.03	62 per 1,000	47 fewer per 1,000(60
hypoglycemia			to 2.02)		fewer to 63 more)
Incidence of preoperative	162 (1 RCT)	LOW 1,5	RR 0.54 (0.18	113 per 1,000	52 fewer per 1,000(93
hypoglycemia			to 1.63)		fewer to 71 more)
Maternal anal discharge time(h)	162 (1 RCT)	LOW ^{1,5}	-	-	MD 0.04 fewer(0.25
		100012			fewer to 0.17 more)
Bleeding during childbirth (ml)	162 (1 RCT)	LOW ^{1,2}	-	-	MD 42.71 fewer
					(82.55 fewer to 2.86 fewer)
Neonatal Apgar scores at 1 min	162 (1 RCT)	LOW 1,5			MD 0.03 more(0.18
					fewer to 0.24 more)
Neonatal Apgar scores at 5 min	162 (1 RCT)	LOW 1,5	-	-	MD 0.03 fewer(0.14
	× ,				fewer to 0.08 more)
Postnatal blood glucose (mmol/L)	162 (1 RCT)	LOW 1,5	-	-	MD 0.45 more(0.03
					fewer to 0.87 more)
Health education: individualization	VS convention				
Fasting blood glucose compli-	110 (1 RCT)	LOW ^{1,5}	RR 1.08(0.86	764 per 1,000	61 more per 1,000(107
ance rate	× ,		to 1.35)		fewer to 267 more)
Glucose-target-rate at 2 o'clock	110 (1 RCT)	LOW 1,2	RR 1.31(1.04	836 per 1,000	259 more per 1,000
			to 1.66)		(33 more to 552
					more)
Glucose-target-rate at 0 o'cl	110 (1 RCT)	LOW ^{1,2}	RR 1.23(1.01	873 per 1,000	201 more per 1,000
			to 1.50)		(9 more to 436
Number constant of Cast		LOW 1,2			more)
Nursing service satisfaction	110 (1 RCT)		-	-	MD 6.51 more(5.80 more to 7.22 more)
					more to 7.22 more

No of partici- pants(studies)	Quality of the evidence	Relative effect (95% Cl)	Anticipated absolute effects		
Follow-up	(GRADE)		Risk with control group	Risk difference with observation group	
ection + Insulin				•	
202 (2 RCTs)	LOW ^{2,3}	-	-	MD 1.17 fewer(1.93 fewer to 0.41 fewer	
202 (2 RCTs)	LOW ^{2,3}	-	-	MD 0.99 fewer(1.61 fewer to 0.36 fewer	
70 (I RCT)	LOW ^{4,5}	-	-	MD 0.62 fewer(1.86 fewer to 0.61 more)	
132 (1 RCT)	LOW ^{2,4}			MD 13.5 fewer (19.02 fewer to 7.98 fewer)	
132 (1 RCT)	LOW ^{2,4}	-		MD 8.59 fewer (13.75 fewer to 3.43	
132 (1 RCT)	LOW ^{4,5}	-		fewer) MD 8 fewer(34.96 fewer to 18.96 more)	
202 (2 RCTs)	LOW ^{3,5}	OR 1.14(0.49 to 2.64)	129 per 1,000	15 more per 1,000(61 fewer to 152 more)	
70 (I RCT)	LOW ^{1,5}	RR 0.21(0.01 to 4.25)	56 per 1,000	44 fewer per 1,000(55 fewer to 181 more)	
	•		•	•	
33 (I RCT)	LOW 1,5	-	-	MD 0.01 more(0.21	
				fewer to 0.23 more)	
33 (I RCT)	LOW ^{1,2}	-	-	MD 0.8 fewer(1.01	
				fewer to 0.59 fewer	
33 (I RCT)	LOW ^{1,2}	-	-	MD 0.76 fewer(I	
	12			fewer to 0.52 fewer	
33 (I RCT)	LOW 1,2	-		MD 0.65 fewer(0.87	
//				fewer to 0.43 fewer	
33 (1 RCT)	LOW ',2	-	-	MD 0.75 fewer(0.96	
	1014 15			fewer to 0.54 fewer	
33 (TRCT)		-	-	MD 0.04 fewer(0.31	
33 (I BCT)	1.0W 1.5	_		fewer to 0.23 more) MD 0.01 fewer(0.2	
				fewer to 0.18 more)	
33 (I RCT)	LOW 1,5	-		MD 0.02 fewer(0.24	
				fewer to 0.2 more)	
33 (I RCT)	LOW 1,5	-		MD 0.05 fewer(0.39	
. ,				fewer to 0.29 more)	
33 (I RCT)	LOW 1,5	-		MD 0.04 fewer(0.35	
				fewer to 0.27 more)	
33 (1 BCT)	1.0W ^{1,5}	RR 1.00/0.89	1.000 per 1.000	0 fewer per 1,000(110	
		to 1.12)	1,000 per 1,000	fewer to 120 more)	
	pants(studies) Follow-up action + Insulin 202 (2 RCTs) 202 (2 RCTs) 70 (1 RCT) 132 (1 RCT) 132 (1 RCT) 132 (1 RCT) 202 (2 RCTs) 70 (1 RCT) 132 (1 RCT) 33 (1 RCT)	pants(studies) evidence (GRADE) Follow-up (GRADE) section + Insulin LOW ^{2,3} 202 (2 RCTs) LOW ^{2,3} 202 (2 RCTs) LOW ^{4,5} 132 (1 RCT) LOW ^{2,4} 132 (1 RCT) LOW ^{4,5} 132 (1 RCT) LOW ^{4,5} 202 (2 RCTs) LOW ^{4,5} 202 (2 RCTs) LOW ^{4,5} 202 (2 RCTs) LOW ^{3,5} 70 (1 RCT) LOW ^{1,5} 33 (1 RCT) LOW ^{1,5} 33 (1 RCT) LOW ^{1,2} 33 (1 RCT) LOW ^{1,5} 33 (1 RCT) L	pants(studies) Follow-up evidence (GRADE) effect (95% Cl) section + Insulin . 202 (2 RCTs) LOW ^{2,3} . 202 (2 RCTs) LOW ^{2,3} . 70 (1 RCT) LOW ^{2,4} . 132 (1 RCT) LOW ^{2,4} . 132 (1 RCT) LOW ^{4,5} . 202 (2 RCTs) LOW ^{4,5} . 132 (1 RCT) LOW ^{3,5} . 202 (2 RCTs) LOW ^{3,5} . 202 (2 RCTs) LOW ^{3,5} . 33 (1 RCT) LOW ^{1,5} . 33 (1 RCT) LOW ^{1,2} . 33 (1 RCT) LOW ^{1,2} . 33 (1 RCT) LOW ^{1,2} . 33 (1 RCT) LOW ^{1,5}	pants(studies) Follow-up evidence (GRADE) effect (5% Cl) absolute effects section + Insulin . . . 202 (2 RCTs) LOW ^{2,3} - . 202 (2 RCTs) LOW ^{2,3} . . 70 (1 RCT) LOW ^{4,5} . . 132 (1 RCT) LOW ^{2,4} . . 132 (1 RCT) LOW ^{4,5} . . 132 (1 RCT) LOW ^{1,5} . . 133 (1 RCT) LOW ^{1,5} . . 33 (1 RCT) LOW ^{1,2} . . 33 (1 RCT) LOW ^{1,2} . . 33 (1 RCT) LOW ^{1,5} .	

Appendix 2. (Continued).

Appendix 2. (Continued). Outcomes No of partici-Quality of the Relative Anticipated evidence effect absolute effects pants(studies) (GRADE) (95% CI) Follow-up **Risk with Risk difference** control group with observation group LOW 1,5 RR 0.31(0.01 33 (I RCT) 43 fewer per 1,000(62 Vausea and vomiting 63 per 1,000 to 7.21) fewer to 388 more) LOW 1,5 RR 2.83(0.12 Uroschesis 33 (I RCT) to 64.89) Postoperative wound care: microwave treatment of VS routine care LOW 1,2 140 (I RCT) RR 1.15(1.03 Wound healing rate at first stage 843 per 1,000 126 more per 1,000 to 1.29) (25 more to 244 more) Psychological intervention (including music therapy) VS routine care Systolic pressure immediately 200 (I RCT) LOW 2,6 MD 9.8 fewer(12.42 into the operating room fewer to 7.18 fewer) (mmHg) LOW 2,6 Systolic pressure after surgery 200 (I RCT) MD 35.37 fewer into the operating room 30min (38.32 fewer to 32.42 fewer) (mmHg) LOW 2,6 Intraoperative systolic pressure 153 (1 RCT) MD 22.63 fewer (mmHg) (27.24 fewer to 18.02 fewer) LOW 2,6 Diastolic pressure immediately 200 (I RCT) MD 3.58 fewer(5.2 into the operating room fewer to 1.96 fewer) (mmHg) LOW 2,6 Diastolic pressure after surgery 200 (I RCT) MD 7.58 fewer(9.62 fewer to 5.54 fewer) into the operating room 30min (mmHg) LOW 2,6 MD 10.61 fewer Intraoperative diastolic pressure 153 (1 RCT) (14.65 fewer to 6.57 (mmHg) fewer) LOW 5,6 Heart rate immediately into the 200 (I RCT) MD 0.86 fewer(2.69 operating room fewer to 0.97 more) LOW 2,6 200 (I RCT) MD 8.89 fewer Heart rate after surgery into the (10.52 fewer to 7.26 operating room 30min fewer) LOW 5,6 Anxiety score immediately into 200 (I RCT) MD 0.13 fewer(2.57 fewer to 2.31 more) the operating room LOW 2,6 200 (I RCT) MD 2.22 fewer(3.55 Anxiety score after surgery into fewer to 0.89 fewer) the operating room 30min 1 OW 2,6 MD 62.39 fewer 153 (1 RCT) Intro-operative hemorrhage (ml) --(78.31 fewer to 46.47 fewer) LOW 2,6 RR 0.73(0.60 Postoperative pains 153 (1 RCT) 855 per 1,000 231 fewer per 1,000 to 0.89) (342 fewer to 94 fewer)

Outcomes	No of partici- pants(studies)	Quality of the evidence	Relative effect	Anticipated absolute effects	5
	Follow-up	(GRADE)	(95% CI)	Risk with control group	Risk difference with observation group
Postoperative normal feeding	153 (1 RCT)	LOW ^{5,6}	RR 1.07(0.99 to 1.16)	908 per 1,000	64 more per 1,000(9 fewer to 145 more)
Postoperative morbidity	153 (I RCT)	LOW ^{2,6}	RR 0.35(0.19 to 0.64)	408 per 1,000	265 fewer per 1,000 (330 fewer to 147 fewer)
Epidural anesthesia vs general ane	sthesia			•	
Blood glucose while skin cutting (mmol/L)	54 (I RCT)	LOW ^{1,2}	-	-	MD 1.48 higher (1.31 higher to 1.56 higher)
Blood glucose while delivery of the fetus (mmol/L)	54 (I RCT)	LOW ^{1,5}	-	-	MD 0 (0.17 lower to 0.17 higher)
Blood glucose while delivery of placenta(mmol/L)	54 (I RCT)	LOW ^{1,2}		-	MD 0.19 fewer(0.37 fewer to 0.1 fewer)
Blood glucose about 2 hours after delivery of the fetus (mmol/L)	54 (I RCT)	LOW ^{1,2}	-	-	MD 0.9 higher(0.71 higher to 1.09 higher)
Blood glucose about 6 hours after delivery of the fetus (mmol/L)	54 (I RCT)	LOW ^{1,2}	-	-	MD 1.11 higher (0.93 higher to 1.29 higher)
Apgar scores <7	54 (I RCT)	LOW ^{1,5}	RR 0.20(0.01 to 3.98)	-	-
Combined spinal and epidural ana	lgesia: low dose sufent	anil combined with bup	ivacaine VS bupiva	caine	
Blood glucose while skin cutting (mmol/L)	66 (I RCT)	LOW ^{1,2}	-	-	MD 1.45 fewer(1.61 fewer to 1.29 fewer
Blood glucose while delivery of the fetus (mmol/L)	66 (I RCT)	LOW ^{1,5}	-	-	MD 0.01 more(0.13 fewer to 0.15 more)
Blood glucose about 5min after delivery of placenta (mmol/L)	66 (I RCT)	LOW ^{1,2}	-	-	MD 0.23 more(0.06 more to 0.4 more)
Blood glucose about 2 hours after delivery of the fetus (mmol/L)	66 (I RCT)	LOW ^{1,2}	-	-	MD 0.89 fewer(1.07 fewer to 0.71 fewer
Mean arterial pressure at Imin after anesthesia (mmHg)	66 (I RCT)	LOW ^{1,5}	-	-	MD 0.4 more(2.11 fewer to 2.91 more)
Mean arterial pressure at 2min after anesthesia (mmHg)	66 (I RCT)	LOW ^{1,5}		-	MD 1.4 more(1.62 fewer to 4.42 more)
Mean arterial pressure at 5min after anesthesia (mmHg)	66 (I RCT)	LOW ^{1,2}	-	-	MD 5.8 more(3.12 more to 8.48 more)
Mean arterial pressure at 10min after anesthesia (mmHg)	66 (I RCT)	LOW 1.5	-	-	MD 0.3 more(2.47 fewer to 3.07 more)
Mean arterial pressure at 20min after anesthesia (mmHg)	66 (I RCT)	LOW ^{1,5}	-	-	MD 1.9 more(1.1 fewer to 4.9 more)

Appendix 2. (Continued).					
Outcomes	No of partici- pants(studies)	Quality of the evidence	Relative effect	Anticipated absolute effects	5
	Follow-up	(GRADE)	(95% CI)	Risk with control group	Risk difference with observation group
Apgar score at Imin	66 (I RCT)	LOW ^{1,5}	-	-	MD 0.1 more(0.17 fewer to 0.37 more)
Apgar score at 5mins	66 (I RCT)	LOW ^{1,2}	-	-	MD 0.1 more(0.02 more to 0.18 more)
Additional an antibiotic once vs 2	4 hours antibiotic applica	ation			
Marked effective rate	120 (I RCT)	LOW ^{1,2}	RR 0.68(0.48 to 0.97)	633 per 1,000	203 fewer per 1,000 (329 fewer to 19 fewer)
Effective rate	120 (1 RCT)	LOW ^{1,5}	RR 1.50(0.97 to 2.33)	333 per 1,000	167 more per 1,000(10 fewer to 443 more)
Inefficient rate	120 (1 RCT)	LOW ^{1,5}	RR 2.00(0.38 to 10.51)	33 per 1,000	33 more per 1,000(21 fewer to 317 more)
Total effective rate	120 (I RCT)	LOW ^{1,5}	RR 0.97(0.89 to 1.05)	967 per 1,000	29 fewer per 1,000 (106 fewer to 48 more)
WBC<12×10 ⁹ /L time (d)	120 (1 RCT)	LOW ^{1,5}	-	-	MD 0.50 more(0.02 fewer to 1.02 more)
Body temperature (no fever and return to normal 48 h after surgery)	120 (1 RCT)	LOW ^{1,5}	RR 0.98(0.93 to 1.04)	983 per 1,000	20 fewer per 1,000(69 fewer to 39 more)
Class-A healing rate	120 (1 RCT)	LOW ^{1,5}	RR 0.97(0.89 to 1.05)	967 per 1,000	29 fewer per 1,000 (106 fewer to 48 more)
Class-B healing rate	120 (1 RCT)	LOW ^{1,5}	RR 2.00(0.38 to 10.51)	33 per 1,000	33 more per 1,000(21 fewer to 317 more)
Class-C healing rate	120 (1 RCT)	-	-	-	-

Appendix 2. (Continued).

*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

GRADE Working Group grades of evidence: high quality: we are very confident that the true effect lies close to that of the estimate of the effect. Moderate quality: we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low quality: our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. Very low quality: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

Notes: No random sequences were reported to generate and assign hidden methods, and no blindness was given to researchers, subjects, and outcome evaluators. ²The sample size is less than the optimal information sample size. ³None of the studies reported randomized generation and allocation of hidden methods, one of which did not blind the researchers and subjects. ⁴The method of generating and assigning hidden random numbers is not reported. ⁵The sample size is less than the optimal information sample size, and the confidence interval of the combined effect is across the invalid line. ⁶No evaluation of the outcome of the blind. The bold values mean the effect or difference was statistically significant. Abbreviation: MD, mean difference.

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Dovepress

Publish your work in this journal

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-targets-and-therapy-journal